Cite
HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy.
MLA
Mavigner, Maud, et al. “HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy.” PLoS ONE, vol. 4, no. 10, Oct. 2009, pp. 1–11. EBSCOhost, https://doi.org/10.1371/journal.pone.0007658.
APA
Mavigner, M., Delobel, P., Cazabat, M., Dubois, M., L’Faqihi-Olive, F.-E., Raymond, S., Pasquier, C., Marchou, B., Massip, P., & Izopet, J. (2009). HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy. PLoS ONE, 4(10), 1–11. https://doi.org/10.1371/journal.pone.0007658
Chicago
Mavigner, Maud, Pierre Delobel, Michelle Cazabat, Martine Dubois, Fatima-Ezzahra L’Faqihi-Olive, Stephanie Raymond, Christophe Pasquier, Bruno Marchou, Patrice Massip, and Jacques Izopet. 2009. “HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy.” PLoS ONE 4 (10): 1–11. doi:10.1371/journal.pone.0007658.